Effect of using fidaxomicin on recurrent Clostridium difficile infection.

Biggs, Martin, Iqbal, Tariq, Holden, Elisabeth, Clewer, V and Garvey, M I (2019) Effect of using fidaxomicin on recurrent Clostridium difficile infection. The Journal of hospital infection, 102 (2). pp. 165-167. ISSN 1532-2939.

Full text not available from this repository.
Official URL: https://linkinghub.elsevier.com/retrieve/pii/S0195...

Abstract

Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.

Item Type: Article
Subjects: WC Communicabable diseases
Divisions: Clinical Support > Infection Control
Clinical Support > Infectious Diseases
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 16 Aug 2019 14:03
Last Modified: 16 Aug 2019 14:03
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2307

Actions (login required)

View Item View Item